Gilead

Gilead to buy US biotech Arcellx for up to US$7.8 billion

The US drugmaker seeks to boost its cancer drug pipeline

Gilead's remdesivir gets US FDA approval for hospitalised Covid-19 patients

Gilead's remdesivir gets US FDA approval for hospitalised Covid-19 patients

[WASHINGTON] The US Food and Drug Administration (FDA) on Thursday approved Gilead Sciences' antiviral drug remdesivir for treating patients hospitalised with Covid-19, making it the first and only dr...

Gilead questions WHO study that cast doubts on drug's Covid-19 benefits

Gilead questions WHO study that cast doubts on drug's Covid-19 benefits

[SWITZERLAND] Gilead Sciences has questioned the findings of a World Health Organization (WHO) study that concluded its Covid-19 drug remdesivir does not help patients who have been admitted to hospit...

Europe buys Gilead's remdesivir for 500,000 Covid-19 patients amid supply worries

Europe buys Gilead's remdesivir for 500,000 Covid-19 patients amid supply worries

[BRUSSELS] Gilead Sciences said on Thursday it had agreed to sell Europe up to 500,0000 courses of its antiviral drug remdesivir, as the continent scrambles to shore up supplies of one of only two dru...

Gilead to buy cancer drugmaker Immunomedics for US$21b

Gilead to buy cancer drugmaker Immunomedics for US$21b

[BENGALURU] Gilead Sciences will acquire biopharmaceutical company Immunomedics for US$21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two compa...

Gilead says additional data on remdesivir shows improved Covid-19 clinical recovery

Gilead says additional data on remdesivir shows improved Covid-19 clinical recovery

[BENGALURU] Gilead Sciences said on Friday additional data from a late-stage study showed its antiviral remdesivir significantly improved clinical recovery and reduced the risk of death in Covid-19 pa...

Australia approves Gilead's remdesivir for Covid-19 treatment

Australia approves Gilead's remdesivir for Covid-19 treatment

[BENGALURU] Australia has granted provisional approval to Gilead Sciences's remdesivir as the first treatment option for Covid-19 in the country, the Therapeutic Goods Administration (TGA) said on Fri...

Gilead's Covid-19 antiviral remdesivir gets conditional EU clearance

Gilead's Covid-19 antiviral remdesivir gets conditional EU clearance

[BRUSSELS] The European Commission said on Friday it had given conditional approval for the use of antiviral remdesivir in severe Covid-19 patients following an accelerated review process, making it t...

Covid-19 drug to cost government entities US$2,340 for 5-day course

Covid-19 drug to cost government entities US$2,340 for 5-day course

GILEAD Sciences said it will charge the US government and other developed countries US$390 per vial for its coronavirus-fighting drug Remdesivir, or about US$2,340 for a typical five-day course of tre...

Gilead's remdesivir endorsed as first Covid-19 treatment in Europe

Gilead's remdesivir endorsed as first Covid-19 treatment in Europe

[BRUSSELS] The European healthcare regulator has recommended the conditional approval of Gilead Sciences' antiviral treatment, remdesivir, for use in Covid-19 patients, making it the first treatment t...